Fusion Antibodies have entered into a partnership with Swiss contract manufacturing organisation Celonic AG to collaborate on the development of high yield stable cell lines. The deal allows clients of Fusion Antibodies a direct & efficient supply path to clinical trial material by taking advantage of the scale-up and development capabilities of Celonic.

Belfast, UK (PRWEB UK) 16 June 2016

UK based contract research organisation Fusion Antibodies and Switzerland based CDMO Celonic, a leading provider of services for the development and cGMP production of biopharmaceuticals, have today announced a partnership to offer Celonic’s CHOvolution cell line development technology to Fusion Antibodies clients.

The collaboration allows Fusion Antibodies’ clients access to the Celonic stable and high titre (>7g/l) platform at an earlier stage and at a competitive cost as the materials are non-GMP and suitable for pre-clinical development. Once a client has completed the applicable preclinical studies, the cell line can be easily transferred from Fusion to Celonic for further development & supply of clinical ready GMP material.

Paul Kerr, Managing Director at Fusion Antibodies commented: “We are delighted to deepen our relationship with Celonic. This partnership allows us to offer our clients a ‘one stop shop’ supply of antibody drug candidate materials from discovery right through to clinical development. Clients do not need to change to a production cell line after their R&D thereby saving time, money and adding project safety as preclinical and clinical results will be easier to compare”

Konstantin Matentzoglu added: “I am excited about this truly enabling partnership, which goes beyond a loose out-licensing/co-marketing deal. Celonic and Fusion Antibodies engage together and will offer highly aligned services to provide a safe and efficient development approach to clients worldwide.”

About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies, Antibody Engineering Projects and cell line development. With 15+ years of experience in the medical research & diagnostic industry, with >60 humanized projects to date (from Rabbit, Rat, Mouse, Llama); Fusion Antibodies have extensive experience in accelerating therapeutic immunotherapy research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a modular package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. The Fusion Antibodies humanization platform produces antibodies which are compliant with the WHO/INN definitions of a humanized antibody to receive the -zu- species origin substem. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Visit their website at http://www.fusionantibodies.com to find out more.

About Celonic
Celonic AG is privately owned CDMO based in Basel, Switzerland providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars worldwide. Applying empathy, efficiency and excellence, Celonic goes one step beyond expectations in all business aspects in order to help its clients attain their goals better, more efficiently and reliably.

advertisement | advertise on newsday

Celonic’s services include the development of cell lines, production processes as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances. In addition, Celonic licenses its proprietary CHOvolution cell line technology to clients, drug developer and service provider.

Visit their website http://www.celonic.com/ to learn more.

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/06/prweb13488853.htm